Cancer Research Institute, ISB, Sage Bionetworks Unveil Comprehensive Immunotherapy Tool


Cancer Research Institute iAtlas Poised to Improve Patient Outcomes by Providing Researchers Greater Access to Genomics Data
FOR IMMEDIATE RELEASE
NEW YORK and SEATTLE – April 5, 2018 – The Cancer Research Institute (CRI), Institute for Systems Biology (ISB) and Sage Bionetworks – three organizations on the forefront of cancer immunotherapy, systems biology and bioinformatics – today announced the release of the Cancer Research Institute iAtlas, a comprehensive web-based tool that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment.
CRI iAtlas is a bioinformatics tool that harnesses immunogenomic data, which were recently published in the journal Immunity. The data are a result of the PanCancer Atlas initiative, the final phase of The Cancer Genome Atlas (TCGA), which investigates more than 10,000 tumor samples across 33 cancer types.
“The Cancer Research Institute, having funded transformative immuno-oncology research for 65 years, decided to support the establishment of an open access database because of the potential impact this tool could have across the field. We expect that the CRI iAtlas will help to accelerate discovery and improve patient outcomes by providing researchers greater access to genomics data to better understand the immunological characteristics of the tumor microenvironment and its potential impact on patient responses to immunotherapy,” said Jill O’Donnell-Tormey, Ph.D., CEO and director of scientific affairs at CRI. “As the CRI iAtlas evolves, we would like to see it become the central repository for this crucial immunogenomics data.”
“The CRI iAtlas tool is the latest iteration of ISB’s focus on providing data resources and visualizations to the research community,” said Ilya Shmulevich, Ph.D., professor at ISB and a core member of the TCGA and iAtlas projects. “With iAtlas, results from the new TCGA study can be harnessed to investigate the immune responses shared among different types of tumors and to explore how immune responses relate to genomic and clinical phenotypes.”
The iAtlas platform is a community resource that opens up previously difficult-to-obtain insights to research organizations of all sizes.
“We are grateful to CRI and the hundreds of researchers who have contributed to this important resource,” said Justin Guinney, Ph.D., vice president of computational oncology at Sage Bionetworks. “The CRI iAtlas platform provides an intuitive and powerful set of web tools that facilitate data exploration and access to an extensive set of immune characterized samples from TCGA.”
Media contacts
Joe Myxter, joe.myxter@systemsbiology.org, 206.732.2157
Brian Brewer, bbrewer@cancerresearch.org, 212.688.7515 x242
Diane Gary, diane.gary@sagebase.org, 206.667.3038
About the CRI iAtlas
The Cancer Research Institute (CRI) iAtlas (www.cri-iatlas.org) is an interactive web-based platform and set of analytic tools for studying interactions between tumors and the immune microenvironment. These tools allow researchers to explore associations among a variety of immune characterizations as well as with genomic and clinical phenotypes. The initial version of CRI iAtlas is based on an analysis performed by The Cancer Genome Atlas (TCGA) Research Network on the TCGA data set comprising over 10,000 tumor samples and 33 tumor samples (Thorsson et al. Immunity, 2018). In this analysis, each tumor sample was scored for a variety of readouts for immune response, such as immune cell composition, adaptive cell receptor repertoire, neoantigen load, and expression of genes coding for immunomodulatory proteins. The web tool allows research to explore these data readouts, and the relation between them in TCGA tumor types and in overarching immune subtypes identified in the study. The CRI iAtlas is made possible through a collaboration between the Cancer Research Institute, Sage Bionetworks and the Institute for Systems Biology.
About the Cancer Research Institute
The Cancer Research Institute (CRI), established in 1953, is the world’s leading nonprofit organization dedicated exclusively to transforming cancer patient care by advancing scientific efforts to develop new and effective immune system-based strategies to prevent, diagnose, treat, and eventually cure all cancers. Guided by a world-renowned Scientific Advisory Council that includes three Nobel laureates and 26 members of the National Academy of Sciences, CRI has invested $357 million in support of research conducted by immunologists and tumor immunologists at the world’s leading medical centers and universities, and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. Learn more at www.cancerresearch.org.
About Sage Bionetworks
Sage Bionetworks is a nonprofit biomedical research organization, founded in 2009, with a vision to promote innovations in personalized medicine by enabling a community-based approach to scientific inquiries and discoveries. Sage Bionetworks strives to activate patients and to incentivize scientists, funders and researchers to work in fundamentally new ways in order to shape research, accelerate access to knowledge and transform human health. It is located on the campus of the Fred Hutchinson Cancer Research Center in Seattle, and is supported through a portfolio of philanthropic donations, competitive research grants, and commercial partnerships. More information is available at www.sagebase.org.
About the Institute for Systems Biology
The Institute for Systems Biology is a nonprofit biomedical research organization based in Seattle. It was founded in 2000 by systems biologist Leroy Hood, immunologist Alan Aderem, and protein chemist Reudi Aebersold. ISB was established on the belief that the conventional models for exploring and funding breakthrough science have not caught up with the real potential of what is possible today. ISB serves as the ultimate environment where scientific collaboration stretches across disciplines and across academic and industrial organizations, where our researchers have the intellectual freedom to challenge the status quo, and where grand visions for breakthroughs in human health inspire a collective drive to achieve the seemingly impossible. Our core values ensure that we always keep our focus on the big ideas that eventually will have the largest impact on human health. ISB is an affiliate of Providence St. Joseph Health, one of the largest not-for-profit health care systems in the United States.
To download the official press release, please click here.
###
Related Articles
-
ISB President Dr. Jim Heath Awarded $750,000 from Andy Hill Cancer Research Endowment
The Andy Hill Cancer Research Endowment (CARE) announced $750,000 in grant funding for Dr. Jim Heath’s work on proactive cancer immunotherapies for initial and recurrent disease. This is the first stage of a planned longer program led by Jim and ISB, and involving Swedish Cancer Institute, Earl A. Chiles Research Institute in Portland, and UW Medicine.
Read More -
ISB’s Computational Teams Play Central Role in Completion of TCGA’s PanCancer Atlas Initiative
ISB’s computational and bioinformatics teams played a central role in the completion of the PanCancer Atlas Initiative, the final phase of TCGA. The culmination of this work is being published in 27 papers this week across the Cell Press research journals, including “The Immune Landscape of Cancer” in Immunity.
Read More -
Genome Comparison Easier with ‘Fingerprint’ Method
ISB researchers have developed a method of capturing a personal genome as a “fingerprint,” which will have a major impact on how quickly and efficiently genome sequences are compared.
Read More
-
TCGA, ISB Researchers Identify Potential Drug Targets for Leading Form of Deadly Liver Cancer
June 19, 2017 Researchers in ISB’s Shmulevich Lab and their colleagues in The Cancer Genome Atlas Research Network performed the first large-scale, multi-platform analysis of hepatocellular carcinoma, the predominant form of liver cancer. Study was published on June 15, 2017, in the journal Cell. 3 Bullets: Liver cancer is the second most common cause of death from cancer worldwide. ISB researchers and colleagues from The Cancer Genome Atlas Research Network…
Read More -
ISB Consilience: Museum of Awe
The Museum of Awe is all around us; you just have to find a door. Attendees of the 2017 Consilience event, including ISB’s Dr. Ilya Shmulevich (center), examine a mini “pop-up” experience created by NASA JPL visual strategists Dan Goods and David Delgado. The tank allows people to see particles that have come down to earth from outer space. The experience is designed as a simple reminder of the gift…
Read More -
Former Undergrad Intern Publishes Algorithm in PLOS Computational Biology
Posted March 1, 2017 In a study published in PLoS Computational Biology, researchers at Institute for Systems Biology (ISB) have developed a multiscale mutation clustering algorithm (M2C) that identifies variable length regions with high mutation density in cancer genes. The M2C algorithm was developed by William Poole (first author on the paper), who started as a summer intern in 2013 as part of ISB’s Center for Systems Biology internship program….
Read More
-
Sanger Institute’s COSMIC database expands cancer cloud capabilities at the Institute for Systems Biology
The Wellcome Trust Sanger Institute released this news on Feb. 20, 2017. See original release… FOR IMMEDIATE RELEASE The Wellcome Trust Sanger Institute’s Catalog of Somatic Mutations in Cancer (COSMIC) team announces a new agreement to provide their data to the U.S.-based Institute for Systems Biology (ISB). COSMIC is an expert-curated cancer mutation database, and is the world’s largest and most comprehensive resource for exploring the impact of somatic mutations…
Read More -
Comprehensive study of esophageal cancer reveals several molecular subtypes, provides new insight into increasingly prevalent disease
The Cancer Genome Atlas Research Network recommends clinical trials organizers and drug manufacturers focus on newly discovered molecular subtypes GRAND RAPIDS, Mich., Jan. 4, 2017 –– A comprehensive analysis of 559 esophageal and gastric cancer samples, collected from patients around the world, suggests the two main types of esophageal cancer differ markedly in their molecular characteristics and should be considered separate diseases. The study, published today in Nature from The…
Read More -
ISB Gets $3.4M NIH Extension for Cancer Genomics Cloud
FOR IMMEDIATE RELEASE ISB Receives $3.4 Million Extension to NIH Contract to Continue Development of ‘Cancer Genomics Cloud’ with Google and CSRA SEATTLE, Oct. 21, 2016 – Institute for Systems Biology (ISB) has received a $3.4 million, one-year extension to an existing federally-funded contract from the National Cancer Institute (NCI), National Institutes of Health (NIH). This follows the completion of the initial two-year, $6.5 million contract during which ISB developed…
Read More
-
Vice President Biden Gives Cancer Moonshot Update
This week, Vice President Biden delivered an extensive update on the progress of the Cancer Moonshot initiative. ISB was mentioned in relation to the Cancer Genomics Cloud project. Learn more about ISB CGC at isb-cgc.org. Excerpt from the official White House press release: Official White House press release Full Cancer Moonshot Report Puget Sound Business Journal article
Read More -
New Baliga Lab Publication in Cell Systems
The Baliga Lab’s Dr. Christopher Plaisier was the lead author of the study “Causal Mechanistic Regulatory Network for Glioblastoma Deciphered Using Systems Genetics Network Analysis” which published online in Cell Systems on July 14. Dr. Plaisier wrote a summary of the research: 3 Bullets: Using data from TCGA and ENCODE, ISB researchers developed integrative database and analysis platforms that provide insight about the underpinnings of glioblastoma multiforme. Researchers developed a…
Read More -
A Landscape of Pharmacogenomic Interactions in Cancer
The journal Cell published a study today (July 7) about the integrated analysis of drug response in 1,001 cancer cell lines. This study was undertaken by a large international group of researchers including ISB Senior Research Scientist Theo Knijnenburg. The researchers integrated heterogeneous molecular data of 11,215 tumors and 1,001 cell lines in order to study the drug response of these cell lines to 265 anti-cancer drugs. They uncovered numerous…
Read More
-
Not Just About Collecting Data
Genetic Engineering & Biotechnology News interviewed ISB’s Dr. Ilya Shmulevich for a feature article on systems biology. “Systems biology is not just about measuring as many things as possible,” says Ilya Shmulevich, PhD, a professor at the Institute for Systems Biology. “It is also about using mathematical and computational modeling to make predictions about the system.” READ THE ARTICLE: http://www.genengnews.com/…/systems-biology-digs-deep…/5775/
Read More -
New Publication in ‘Cancer Cell’
As part of The Cancer Genome Atlas project, the Shmuelvich Lab and colleagues published a paper in the journal Cancer Cell related to the rare cancer adrenocortical carcinoma. Read the summary: 3 Bullets: Adrenocortical carcinoma (ACC) is a rare, under-researched endocrine cancer with limited therapeutic options and overall poor outcome. TCGA researchers performed comprehensive analysis of 91 ACC samples to gain better understanding of potential genetic causes of the cancer….
Read More -
ISB Researcher Featured in Bio-IT World
Congrats to Sheila Reynolds (Shmulevich Lab) on being featured on the Bio-IT World Conference site for her presentation on ISB’s Cancer Genomics Cloud project. Read the Q&A here. Excerpt below: Cancer Genome Analysis at the Institute for Systems Biology Q1: How did your background in signal processing and machine learning lead you to work in cancer genome analysis at the Institute for Systems Biology in Seattle, Washington? After working in…
Read More
-
Using Google Cloud Platform to Give Researchers Easier Access to Cancer Data
ISB’s Dr. Ilya Shmulevich attended Google Cloud Platform’s GCPNext conference in San Francisco and presented on ISB’s Cancer Genomics Cloud project. He explains how his team used GCP to create better access for a broad range of researchers to cancer genomics data (from The Cancer Genomics Atlas) and the tools with which to explore that data. Watch Dr. Shmulevich’s talk below.
Read More -
ISB’s Cancer Genomics Cloud Team Launches BigQuery Platform
Genomeweb published an article on the Cancer Genomics Cloud pilots. Learn more about ISB’s CGC project. PDF: Cancer Genomics Cloud Pilot Developers Provide Update, Open Up Platforms for Early Testing | GenomeWeb NEW YORK (GenomeWeb) – The developers of the three proposals selected by the National Cancer Institute for the Cancer Genomics Cloud pilots — an effort to build sustainable computing infrastructure for analyzing omics data from the Cancer Genome…
Read More -
ISB Launches 3-Year Wilke Lyme Disease Project with $2.13M Funding
Study Utilizes Systems Approaches to Develop Diagnostics and Deeper Understanding of Chronic Lyme PRESS RELEASE, SEATTLE, March 26, 2015 – Institute for Systems Biology (ISB) has received $2.13 million in transformational gifts from Jeff and Liesl Wilke; Jeff and MacKenzie Bezos; and the Bay Area Lyme Foundation to tackle chronic Lyme disease, a highly complex and often misdiagnosed disease that can be debilitating for those who do not respond to…
Read More
-
Into the genetic weeds of hair growth
3 Bullets: ISB researchers used a data-driven mathematical model to identify specific genes associated with hair regeneration Novel methodology paves way for continued research into the molecular basis of this complex cycle as well as other regenerative organs like skin and liver Findings may lead to more precise targets for therapies and genetic markers of hair wellness By Varsha Dhankani Scientists at ISB have identified genes associated with the growth-and-death…
Read More -
Cancer Genomics Cloud: ISB and Google Featured in MIT Tech Review
(Above illustration from MIT Technology Review.) MIT Technology Review published an article about the launch of Google Genomics and included a mention of ISB’s new Cancer Genomics Cloud project. ISB received an up-to $6.5 million, two-year NIH contract in collaboration with Google and SRA International. From the MIT Technology Review article: The idea is to create “cancer genome clouds” where scientists can share information and quickly run virtual experiments as…
Read More -
How Physics and Thermodynamics Help Assess DNA Defects in Cancer
3 Bullets: ‘Big data’ cancer research has revealed a new spectrum of genetic mutations across tumors that need understanding. Existing methods for analyzing DNA defects in cancer are blind to how those mutations actually behave. ISB scientists developed a new approach using physics- and structure-based modeling to systematically assess the spectrum of mutations that arise in several gene regulatory proteins in cancer. By Jake Valenzuela and Justin Ashworth A significant…
Read More
-
New Details on Thyroid Cancer May Lead to More Precise Therapies
3 Bullets: Papillary thyroid cancer represents 80 percent of all thyroid cancer cases. Integrative analysis resulted in the detection of significant molecular alterations not previously reported in the disease. ISB researchers identified microRNAs which may lead to more precise therapy. By Lisa Iype Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, accounting for 80 percent of all cases. As part of The Cancer Genome Atlas (TCGA)…
Read More -
It’s Easier to Go ‘Viral’ When Your Partner Happens to be Google
By ISBUSA Since we announced that we got a $6.5 million contract from NCI to develop the Cancer Genomics Cloud pilot project, we’ve gotten some great press from around the world. It doesn’t hurt that one of our partners is Google, of course. Here are some of the headlines from around the world: Puget Sound Business Journal: Cancer in the cloud: Institute for Systems Biology teams up with Google NBCNews.com:…
Read More -
ISB Awarded $6.5 Million NIH Contract to Develop ‘Cancer Genomics Cloud’ with Google and SRA International
PRESS RELEASE Institute for Systems Biology (ISB) has received a $6.5 million, up to two-year, federally funded contract from the National Cancer Institute (NCI), National Institutes of Health (NIH). ISB is one of three organizations awarded a contract by NCI to develop a cloud-based platform that will serve as a large-scale data repository and provide the computational infrastructure necessary to carry out cancer genomics research at unprecedented scales. ISB’s Shmulevich…
Read More
-
Analyzing Family Genomics Reveals New Culprit in Rare Disease
3 Bullets: Adams-Oliver syndrome (AOS) is a rare congenital disease characterized by scalp lesions and limb defects. Additional vascular abnormalities and heart defects can lead to early death in some patients. By analyzing twelve families affected with the disease, we identified causal mutations in a new disease gene, NOTCH1, in five families. NOTCH1 is likely to be the major cause of AOS. NOTCH1 codes for a transcription factor that governs…
Read More -
BIOCELLION: New Supercomputer Software Framework Models Biological Systems at Unprecedented Scales
3 Bullets: Computer simulation is a promising way to model multicellular biological systems to help understand complexity underlying health and disease. Biocellion is a high-performance computing (HPC) framework that enables the simulation of billions of cells across multiple scales. Biocellion facilitates researchers without HPC expertise to easily build and simulate large models. By Theo Knijnenburg How do molecular changes, such as a mutation in the DNA or infection by a…
Read More -
ISB Researchers Help Identify Four New Subtypes of Gastric Cancer That May Lead to New Targeted Treatments
3 Bullets: Gastric cancer has a high mortality rate, but current classification systems haven’t been effective in helping to identify subtypes relevant for treatment of the disease. TCGA researchers have integrated molecular data from 295 stomach tumors and have discovered four subtypes of gastric cancer. Stratification of patients into these four subtypes paves the way for the development of new personalized therapies. By Theo Knijnenburg Gastric cancer is among the…
Read More
-
3-Minute Science: ISB and Seattle BioMed Hold Annual Lightning Talks
Photo: Theo Knijnenburg, a research scientist in ISB's Shmulevich Lab, presentaed a summary of his work related to gene mutations and cancer drug sensitivity. Systems biology is about the culture as much as a scientific approach. ISB and Seattle BioMed have an inter-institutional agreement that enables the collective to benefit from shared knowledge and technology resources. For the second consecutive year, we held Lightning Talks (June 12) to allow researchers…
Read More -
Cancer Stratification: A Systems Approach
By Theo Knijnenburg ISB Editorial Board Member When a patient receives a diagnosis of breast cancer, it’s a specific subtype of breast cancer, such as invasive ductal carcinoma. Each subtype is characterized by the shape and location of the tumor, its growth progression, prognosis and treatment. The ability to stratify, or group, cancer patients based on the specific characteristics of their cancer type, is the first step toward personalized cancer…
Read More -
Cancer Treatment: A Systems Approach
By Sui Huang and Joseph Zhou, ISB Editorial Board Members Cancer cells, for decades regarded as a uniform mass of identical (“clonal”) cells, are not like the soldiers of a traditional army, trained to act and respond in unison. Cancer cells, even within a genetic clone, express enormous individuality akin to guerrilla fighters, each with unique strengths, weaknesses and distinct behaviors. Therefore, they do not respond to an attack from…
Read More
-
ISB’s Annual Symposium
ISB held its 13th Annual International Symposium: Systems Biology & Cancers From Big Data to Personalized Treatment on April 13-14, 2014. Visit symposium.systemsbiology.net for details. Visit the gallery for images. Or visit the video playlist on ISB’s YouTube channel.
Read More -
ISB Senior Software Engineers Win BioVis Award
Congratulations to Dick Kreisberg, Ryan Bressler, Sheila Reynolds, Brady Bernard and Ilya Shmulevich on winning "Best Poster" at the BioVis 2013 conference in Atlanta, Georgia. Here's a link to the poster description. Ryo Sakai, who is currently a visiting researcher in the Shmulevich group from KU Leuven in Belgium, received honorable mention in both the "Redesign Contest" and the "Data Contest." Data science for the win!
Read More -
Largest Genetics Catalog of Deadliest Brain Tumor Released
By Varsha Dhankani Glioblastoma multiforme (GBM) is the most common and deadliest of malignant primary brain tumors in adults. Because of its lethality, GBM was selected as the first brain tumor to be sequenced as part of The Cancer Genome Atlas (TCGA), a comprehensive project funded by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to map the genomes of more than 25 types…
Read More
-
ISB Hosts TCGA Meeting
Ilya Shmulevich, PhD, shares this message about our hosting a TCGA (The Cancer Genome Atlas) steering committee meeting at ISB. In the video below, Ilya explains the purpose of the meeting and chats briefly about “pan-cancer” – the effort to find commonalities among multiple cancers. Related content: Read about ISB’s role in TCGA as a Genome Data Analysis Center and about the most recent collaborative paper on endometrial cancer, which…
Read More -
ISB Takes 1st Place in YarcData Contest
Dr. Brady Bernard, Andrea Eakin, and Dr. Ilya Shmulevich, of The Institute for Systems Biology (ISB), were awarded first prize and will split $70,000 for their winning entry researching more than 25 different types of cancers and thousands of patients to gain insight into the biological networks that are disrupted or altered within a given cancer type and to identify potentially potent approved drugs that could be repurposed for the…
Read More -
A Personal Love
ISB Senior Researcher Shares Ode to DNA By Jared Roach, MD, PhD Here is my personal ode to DNA. Valentine’s day is coming and this ode is overdue. For those of you attending my talk on personal genome sequencing tonight (Monday, February 11) at 7 p.m. at Wilde Rover in Kirkland, I have put in some links to books that I think you might really enjoying reading. What does the…
Read More
-
A Personal Love: ISB Senior Scientist Shares Ode to DNA
By Jared Roach, MD, PhD Here is my personal ode to DNA. Valentine’s day is coming and this ode is overdue. For those of you attending my talk on personal genome sequencing tonight (Monday, February 11) at 7 p.m. at Wilde Rover in Kirkland, I have put in some links to books that I think you might really enjoying reading. What does the genome mean to me personally? How is…
Read More -
ISB at Eastside Science Cafe
Personal Genome Sequencing Discussion at Eastside Science Cafe. Jared Roach, Ph.D., M.D., Institute for Systems Biology, will be presenting at Eastside Science Cafe: Monday, 11 February 2013 – 7:00pm Location: Wilde Rover, Kirkland Click here for Map The first personal genomes were sequenced only five years ago and cost millions of dollars. Personal genome sequencing is now a thousand times cheaper, and many people are considering sequencing their own genomes…
Read More -
ISB’s Role in TCGA
When you see a reference to “cancer research,” you know that it’s important. But do you really know what it means and how complex the research is? Many ISB scientists are entrenched in molecular cancer research. To better appreciate what they’re tackling, let’s talk about The Cancer Genome Atlas (TCGA) project. In understanding cancers, researchers first have to know what errors in the DNA of tumor cells cause them to…
Read More
-
An Evening to Remember
About 20 years ago, Carole Ellison attended a lecture by Dr. Lee Hood shortly after he had arrived at the University of Washington to start the Department of Molecular Biotechnology. She was impressed by his vision for the future of science and healthcare and vowed to meet him one day. This wish and her lifelong interest in science and human health led her to ISB. This summer, Carole finally was…
Read More -
ISB Co-Authored Nature Paper Featured in the New York Times
The Ilya Shmulevich Group at ISB has been participating in The Cancer Genome Atlas (TCGA) project as a Genome Data Analysis Center. The first paper resulting from the main phase of the TCGA project – "Comprehensive molecular characterization of human colon and rectal cancer" – was published in the July 19, 2012, issue of Nature and also featured on the front page of the New York Times. ISB teamed up…
Read More -
ISB Featured in Google I/O Conference Keynote
We were very excited to watch the live stream of the keynote from the Google I/O conference today, because it featured work from ISB's Shmulevich Lab, which is one of a group of research organizations that has been working on The Cancer Genome Atlas (TCGA). To help visualize the TCGA data, the lab created the Cancer Regulome Explorer using Google App Engine and Google Compute Engine. Google Compute Engine is…
Read More
-
Watch Cracking Your Genetic Code on PBS. See more from NOVA.
Lee Hood Talks Actionable Genes in NOVA’s ‘Cracking Your Genetic Code’
If you missed the NOVA special "Cracking Your Genetic Code" you can watch it here. Our president, Lee Hood, was among the experts featured in the documentary.
Read More -
Genome Ethics
By Chris Witwer The Health and Human Service human research regulations are being revised. Scientists' input on whole genome sequencing data may shape the future of research. It's great that the article below says that change is "imminent." Here's an article that describes the issue: DNA Mapped in a Day Prompts U.S. Review of Genome Ethics And here's a document from the Department of Health and Human Services: https://s3.amazonaws.com/public-inspection.federalregister.gov/2012-07329.pdf The…
Read More -
Watch Cracking Your Genetic Code Preview on PBS. See more from NOVA.
Lee Hood on NOVA on March 28
We are eager to watch the NOVA documentary tonight on PBS called "Cracking Your Genetic Code." Lee Hood is one of the featured experts. The producer, Sarah Holt, began with a series of phone interviews late last summer before interviewing Lee on camera in her Boston studio. Here's a preview radio segment on the Emily Rooney Show that features Holt and Dr. Rudy Tanzi, who also appears in the documentary….
Read More
-
Our Genomes, Our Selves: The hunt for a disease gene
By Lee Rowen Every once in a while, different components of a research problem come together at just the right time. One lives for, and savors, these occasions. One of my favorite examples is the discovery of the genetic variant that causes hereditary pancreatitis. Hereditary pancreatitis (HP) causes painful attacks of the gut, often beginning in childhood. Over time, the pain and damage can become chronic and there is an…
Read More -
Personalized Medicine: From Bench to Clinic
Our president, Dr. Leroy Hood, is featured in this Genome Technology article about the challenges of moving personalized medicine into the clinic. (The cover image features Dr. Eric Topol, who recently published a book called "The Creative Destruction of Medicine.")
Read More -
All Hope is Not Lost for Better Healthcare
By Jeremy Johnson I used to feel a hopelessness about modern healthcare. We would talk in circles about how some people would get the care they needed, others would not, and that was the way of the world. Being what the insurance company calls a “young and healthy,” I had the luxury of watching the game unfold, but I didn’t have anything personal at stake. Then, a few Novembers back,…
Read More
-
Our Genomes, Our Selves
By Lee Rowen In February of 2001 I headed off to Washington DC to participate in an extravagant celebration of scientific achievement. Preliminary drafts of the human genome’s DNA sequence were being published in Nature and Science magazines, and those of us who’d spent years immersed in the Human Genome Project were ready to exult, for one precious weekend, before spending yet more years finishing the sequence to high quality….
Read More